Latest Breaking News On - ர்யாஸா போகாரி - Page 1 : comparemela.com

FSD Pharma Inc appoints Anthony Durkacz as its new interim chief executive officer

FSD Pharma Inc appoints Anthony Durkacz as its new interim chief executive officer
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Raza bokhariZeeshan saeedAnthony durkaczBiosciences incர்யாஸா போகாரிஜீஷந் சயீத்உயிர் அறிவியல் இன்க்

FSD Management and Board Suffers Multiple Court Losses as Shareholder Meeting Approaches

/PRNewswire/ - On Monday, May 10, 2021, at the request of Messrs. Anthony Durkacz and Zeeshan Saeed, founding shareholders and members of the group of.

Raza bokhariZeeshan saeedCarol hansellAnthony durkaczRick santorumFrank lavelleCourt orderJustice commercial list the courtOntario superior courtCourt order the companyPharma incCommercial listConcerned shareholderConcerned shareholdersSenator rick santorumSenator santorum

FSD Pharma Announces That ISS Recommends Shareholders Vote for the Company s Nominees to the Board Using Only the BLUE Proxy

Search jobs 05-May-2021 FSD Pharma Announces That ISS Recommends Shareholders Vote for the Company’s Nominees to the Board Using Only the BLUE Proxy Shareholders URGED to Vote the BLUE proxy by 9:00 a.m. on May 12, 2021 TORONTO (BUSINESS WIRE) $HUGE FSD Pharma Inc. (the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent international corporate governance analysis and proxy advisory firm, has recommended that shareholders vote FOR all Company Director Nominees (the Management Director Nominees ) in a contested election for the Board of Directors and FOR the elimination of the dual-class share structure (the Dual-Class Sunset ) at the annual and special meeting of shareholders on May 14, 2021 (the Meeting ).

United statesRaza bokhariNathan coyleZeeshan saeedAnthony durkaczBiosciences incNeither the canadian securities exchangeGryphon advisors incPharma incInstitutional shareholder services incInstitutional shareholder servicesCompany director nomineesManagement director nomineesDual class sunsetExecutive chairmanManagement director

Concerned Shareholders of FSD: Concerned Shareholders Issue Information Circular for FSD Pharma Inc Shareholders Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy

Concerned Shareholders of FSD: Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders Meeting - Urge Shareholders to Vote Their Shares Using the Gold Proxy Concerned Shareholders ) of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) (the Company or FSD ) filed and mailed an information circular and gold proxy to FSD s shareholders for the upcoming annual general and special meeting of FSD to be held on May 14, 2021 (the Meeting ). The Concerned Shareholders are urging FSD shareholders to help rebuild FSD by replacing the current board of directors (other than Anthony Durkacz) at the Meeting by voting their shares using the GOLD PROXY to elect the five highly qualified and experienced candidates nominated by the Concerned Shareholders, Anthony Durkacz, Zeeshan Saeed, Nitin Kaushal, Larry Latowsky and Fernando Cugliari (the

Raza bokhariZeeshan saeedNitin kaushalChristine carsonLarry latowskyAnthony durkaczNewsfile corpOntario superior courtPharma incCarson proxy advisors ltdConcerned shareholdersFernando cugliariCommercial listConcerned shareholder nomineesர்யாஸா போகாரிஜீஷந் சயீத்

FSD Pharma Inc throws resources behind legacy anti-inflammatory drug as potential coronavirus therapy

Launched Phase 2 study of drug known as micro PEA in December 2020 Developing drugs to treat gastrointestinal diseases in dogs and cats FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) is a publicly-traded holding company that owns subsidiary FSD Pharma BioSciences Inc, a specialty biotech pharmaceutical R&D firm focused on developing multiple applications of its lead anti-inflammatory drug FSD-201. The drug is now one of several therapeutics being advanced that could help reduce severe and deadly lung infection in coronavirus (COVID-19) patients. Known as ultra-micronized PEA, the drug is a naturally occurring fatty acid similar to an endocannabinoid, one of a suite of molecules found in cannabis that targets endocannabinoid (CB2) receptors in the human body. The company holds exclusive worldwide rights to the drug that has been used for 40 years to fight respiratory infections - except in Italy and Spain, where PEA is prescribed as a medical-food supplement to treat chronic infla

Raza bokhariInnovet italiaEdward brennanBiosciences incDrug administrationEnzyme linked immunosorbent assayInvestigational animal drug applicationNew animal drug applicationர்யாஸா போகாரிஎட்வர்ட் ப்ரென்னன்உயிர் அறிவியல் இன்க்புதியது விலங்கு மருந்து விண்ணப்பம்